MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Head and Neck Squamous Cell Carcinoma

  • Home
  • Head and Neck Squamous Cell Carcinoma
Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial
Posted innews Oncology Otorhinolaryngology

Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial

Posted by By MedXY 09/21/2026
PDS0101 combined with pembrolizumab demonstrated encouraging efficacy and safety in immune checkpoint inhibitor-naive HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, supporting further first-line evaluation.
Read More
Optimizing Monitoring in Head and Neck Squamous Cell Carcinoma: Tissue-Informed ctDNA Assay Shows High Accuracy and Feasibility
Posted innews Oncology Otorhinolaryngology

Optimizing Monitoring in Head and Neck Squamous Cell Carcinoma: Tissue-Informed ctDNA Assay Shows High Accuracy and Feasibility

Posted by By MedXY 09/07/2026
Tissue-informed circulating tumor DNA assays demonstrate high detection rates and exceptional sensitivity and specificity in monitoring HPV-positive and HPV-negative head and neck squamous cell carcinoma, supporting their clinical utility in disease management.
Read More
Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy
Posted innews Oncology Otorhinolaryngology

Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy

Posted by By MedXY 08/25/2026
Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.
Read More
Harnessing Cancer-Testis Antigens for Precision Immunotherapy in Head and Neck Cancer
Posted inOncology Pathology & Lab Medicine Superintelligence

Harnessing Cancer-Testis Antigens for Precision Immunotherapy in Head and Neck Cancer

Posted by By MedXY 10/24/2025
This study identifies specific cancer-testis antigens (CTAs) as promising targets for personalized immunotherapy in head and neck squamous cell carcinoma (HNSCC), validated across multiomic datasets to enhance therapeutic precision.
Read More
Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma
Posted inClinical Updates news Oncology

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

Posted by By MedXY 09/04/2025
A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.
Read More
  • DOACs versus Warfarin for Cerebral Venous Thrombosis: Noninferiority Confirmed in Large-Scale Chinese Registry Study
  • Focal Congenital Hyperinsulinism: Insights Into Spontaneous Glycemic Improvement Before Surgical Intervention
  • Return to Competition and Career Sustainability After Primary ACL Reconstruction in Football: Insights from Nationwide and Long-Term Studies
  • Predicting Walking Ability in Nontraumatic Spinal Cord Injury Using Machine Learning: A Novel Temporal Validation Study
  • Decoding Fluoride Discourse on X During the 2024 US Presidential Election: Implications for Public Health Communication
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top